<a href="https://laohu8.com/S/CRSP">CRISPR Therapeutics AG</a> Announces Collaboration with Sirius <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Develop Next-Gen siRNA Therapy Targeting Thrombosis
CRISPR Therapeutics AG has announced a significant collaboration with Sirius Therapeutics, involving a Collaboration, Option and License Agreement. This partnership aims to advance the research, development, manufacture, and commercialization of innovative siRNA technology targeting Factor XI. A key focus of this collaboration is the co-development and commercialization of SRSD107, a next-generation siRNA designed to inhibit human coagulation factor XI, which is implicated in pathological thrombosis. This collaboration aims to reduce thrombotic events with minimal bleeding risk. The agreement includes options for CRISPR Therapeutics to exclusively license Sirius' siRNA technology for up to two additional targets, with potential milestone payments totaling $87.5 million. Both companies have committed to exclusivity in this field, prohibiting any siRNA-based advances targeting factor XI outside of this partnership.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-074428), on May 19, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。